This site is intended for healthcare professionals

Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase IIb dose-ranging induction trial.- InDEx Pharma and Merck KGaA

Read time: 1 mins
Last updated:26th Oct 2020
Published:23rd Oct 2020
InDex Pharmaceuticals Holding AB (publ) announced that the results of the CONDUCT study have been published in the high-impact medical journal The Lancet Gastroenterology and Hepatology.
Condition: Ulcerative Colitis
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest